Diskussionsleitung: H. Treede (Mainz), N. Werner (Trier)
| (P1310) | Impact of vascular access site complications for long-term mortality after transfemoral transcatheter aortic valve implantation (tf-TAVI) in a real-world setting | |
| L. Baez, D. Kretzschmar, M. Diab, M. Franz, C. Schulze, M. Franz, S. Möbius-Winkler (Jena, Goslar) | ||
| (P1311) | Characteristics and outcome of arterial pseudoaneurysm formation after large-bore femoral access site closure with a plug-based device: an analysis from the randomized CHOICE-CLOSURE trial | |
| A. Abdelhafez, M. Abdel-Wahab, O. Dumpies, P. Hartung, P. Boekstegers, M. M. Vorpahl, T. Noack, N. Majunke, S. Desch, H. Thiele (Leipzig, Siegburg, Wuppertal) | ||
| (P1312) | The Role of access site calcification in conventional and echo guided puncture during TAVI | |
| M. Potratz, Z. Simmance, H. Omran, S. Scholtz, R. Schramm, V. Rudolph, S. Bleiziffer, T. K. Rudolph (Bad Oeynhausen) | ||
| (P1313) | Early outcome of a novel percutaneous vascular closure device in endoscopic mitral valve surgery | |
| J. Pausch, H. Sarwari, O. Bhadra, X. Hua, A. Schäfer, H. Reichenspurner, L. Conradi (Hamburg) | ||
| (P1314) | Safety and efficacy of protamine administration for prevention of bleeding complications in patients with recent PCI undergoing TAVR | |
| B. Al-Kassou, D. Anastasoudis, A.-S. Hasanin, J. Shamekhi, A. Aksoy, D. Nelles, A. Sugiura, M. Weber, E. Grube, F. Bakhtiary, H. Möllmann, G. Nickenig, V. Tiyerili, S. Zimmer (Bonn, Dortmund) | ||
| (P1315) | Efficacy and Safety of Low-Dose Protamine in Reducing Bleeding Complications during TAVI: A Propensity-Matched Comparison | |
| K. Kneizeh, A. Milzi, F. Vogt, K. Witte, N. Marx, M. Lehrke, M. Almalla, J. Schröder, für die Studiengruppe: TAVI Aachen (Aachen) | ||
| (P1316) | Blutungen unter NOAK-Therapie bei TAVI-Patienten | |
| A. Polzin, C. Helten, D. Metzen, S. Zako, P. Mourikis, V. Veulemans, M. Kelm, T. Zeus (Düsseldorf) |